{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:57:31Z","timestamp":1790899051405,"version":"4.1.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,16]],"date-time":"2015-11-16T00:00:00Z","timestamp":1447632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1038\/nrneph.2015.180","type":"journal-article","created":{"date-parts":[[2015,11,16]],"date-time":"2015-11-16T05:27:11Z","timestamp":1447651631000},"page":"37-47","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":152,"title":["HDL abnormalities in nephrotic syndrome and chronic kidney disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Nosratola D.","family":"Vaziri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,16]]},"reference":[{"key":"BFnrneph2015180_CR1","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.2337\/db09-0538","volume":"58","author":"M Navab","year":"2009","unstructured":"Navab, M., Anantharamaiah, G. M., Reddy, S. T., Van Lenten, B. J. & Fogelman A. M. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes 58, 2711\u20132717 (2009).","journal-title":"Diabetes"},{"key":"BFnrneph2015180_CR2","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1046\/j.1523-1755.2003.00941.x","volume":"63","author":"ND Vaziri","year":"2003","unstructured":"Vaziri, N. D. Molecular mechanisms of lipid dysregulation in nephrotic syndrome. Kidney Int. 63, 1964\u20131976 (2003).","journal-title":"Kidney Int."},{"key":"BFnrneph2015180_CR3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1152\/ajprenal.00099.2005","volume":"290","author":"ND Vaziri","year":"2006","unstructured":"Vaziri, N. D. Dyslipidemia of chronic renal failure: the nature, mechanisms and potential consequences. Am. J. Physiol. Renal Physiol. 290, 262\u2013272 (2006).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph2015180_CR4","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1046\/j.1523-1755.63.s84.3.x","volume":"84","author":"PO Attman","year":"2003","unstructured":"Attman, P. O., Samuelsson, O., Johansson, A. C., Moberly, J. B. & Alaupovic, P. Dialysis modalities and dyslipidemia. Kidney Int. 84, S110\u2013S112 (2003).","journal-title":"Kidney Int."},{"key":"BFnrneph2015180_CR5","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.jrn.2010.05.010","volume":"20","author":"ND Vaziri","year":"2010","unstructured":"Vaziri, N. D. Lipotoxicity and impaired HDL-mediated reverse cholesterol\/lipid transport in chronic kidney disease. J. Ren. Nutr. 20, S35\u2013S43 (2010).","journal-title":"J. Ren. Nutr."},{"key":"BFnrneph2015180_CR6","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0272-6386(00)70255-1","volume":"35","author":"CJ Deighan","year":"2000","unstructured":"Deighan, C. J., Caslake, M. J., McConnell, M., Boulton-Jones, J. M. & Packard, C. J. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am. J. Kidney Dis. 35, 852\u2013862 (2000).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2015180_CR7","first-page":"381","volume":"50","author":"BM Wilkes","year":"1998","unstructured":"Wilkes, B. M., Reiner, D., Kern, M. & Burke, S. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin. Nephrol. 50, 381\u2013386 (1998).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph2015180_CR8","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1161\/CIRCULATIONAHA.109.897330","volume":"121","author":"Y Zhang","year":"2010","unstructured":"Zhang, Y. et al. Adipocyte modulation of high-density lipoprotein cholesterol. Circulation 121, 1347\u20131355 (2010).","journal-title":"Circulation"},{"key":"BFnrneph2015180_CR9","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1172\/JCI30163","volume":"116","author":"DJ Rader","year":"2006","unstructured":"Rader, D. J. Molecular regulation of HDL metabolism and function: implications for novel therapies. J. Clin. Invest. 116, 3090\u20133100 (2006).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph2015180_CR10","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1021\/bi952242v","volume":"35","author":"Y Zhao","year":"1996","unstructured":"Zhao, Y. & Marcel, Y. L. Serum albumin is a significant intermediate in cholesterol transfer between cells and lipoproteins. Biochemistry 35, 7174\u20137180 (1996).","journal-title":"Biochemistry"},{"key":"BFnrneph2015180_CR11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/B978-0-12-382171-3.10002-6","volume-title":"The HDL Handbook","author":"NJ Hime","year":"2010","unstructured":"Hime, N. J. in The HDL Handbook (ed. Komoda, T.) 17\u201333 (Academic Press, 2010)."},{"key":"BFnrneph2015180_CR12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0021-9150(01)00447-6","volume":"155","author":"J Huuskonen","year":"2001","unstructured":"Huuskonen, J., Olkkonen, V. M., Jauhiainen, M. & Ehnholm, C. The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis 155, 269\u2013281 (2001).","journal-title":"Atherosclerosis"},{"key":"BFnrneph2015180_CR13","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1126\/science.271.5248.518","volume":"271","author":"S Acton","year":"1996","unstructured":"Acton, S. et al. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271, 518\u2013520 (1996).","journal-title":"Science"},{"key":"BFnrneph2015180_CR14","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/89986","volume":"7","author":"IS Yuhanna","year":"2001","unstructured":"Yuhanna, I. S. et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7, 853\u2013857 (2001).","journal-title":"Nat. Med."},{"key":"BFnrneph2015180_CR15","doi-asserted-by":"crossref","first-page":"9142","DOI":"10.1074\/jbc.M211394200","volume":"278","author":"C Mineo","year":"2003","unstructured":"Mineo, C. et al. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J. Biol. Chem. 278, 9142\u20139149 (2003).","journal-title":"J. Biol. Chem."},{"key":"BFnrneph2015180_CR16","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1172\/JCI35470","volume":"118","author":"N Terasaka","year":"2008","unstructured":"Terasaka, N. et al. ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J. Clin. Invest. 118, 3701\u20133713 (2008).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph2015180_CR17","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1161\/ATVBAHA.106.136325","volume":"27","author":"RS Birjmohun","year":"2007","unstructured":"Birjmohun, R. S. et al. High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. Arterioscler. Thromb. Vasc. Biol. 27, 1153\u20131158 (2007).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrneph2015180_CR18","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1681\/ASN.2011070668","volume":"23","author":"T Weichhart","year":"2012","unstructured":"Weichhart, T. et al. Serum amyloid A in uremic HDL promotes inflammation. J. Am. Soc. Nephrol. 23, 934\u2013947 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2015180_CR19","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1161\/01.ATV.15.11.1987","volume":"15","author":"GW Cockerill","year":"1995","unstructured":"Cockerill. G. W. et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 15, 1987\u20131994 (1995).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrneph2015180_CR20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.atherosclerosis.2010.05.035","volume":"212","author":"S Patel","year":"2010","unstructured":"Patel S. et al. Anti-inflammatory effects of apolipoprotein A-I in the rabbit. Atherosclerosis 212, 392\u2013397 (2010).","journal-title":"Atherosclerosis"},{"key":"BFnrneph2015180_CR21","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/ATVBAHA.108.168690","volume":"28","author":"AJ Murphy","year":"2008","unstructured":"Murphy, A. J. et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler. Thromb. Vasc. Biol. 28, 2071\u20132077 (2008).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrneph2015180_CR22","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1161\/01.ATV.0000079011.67194.5A","volume":"23","author":"T Kimura","year":"2003","unstructured":"Kimura, T. et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol. 23, 1283\u20131288 (2003).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrneph2015180_CR23","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1006\/bbrc.2000.2877","volume":"272","author":"M Sugano","year":"2000","unstructured":"Sugano, M., Tsuchida, K. & Makino, N. High-density lipoproteins protect endothelial cells from tumor necrosis factor-\u03b1-induced apoptosis. Biochem. Biophys. Res. Commun. 272, 872\u2013876 (2000).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrneph2015180_CR24","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1161\/01.ATV.17.10.2158","volume":"17","author":"I Suc","year":"1997","unstructured":"Suc, I. et al. HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 17, 2158\u20132166 (1997).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrneph2015180_CR25","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1161\/01.RES.74.6.1149","volume":"74","author":"G Murugesan","year":"1994","unstructured":"Murugesan, G., Sa, G. & Fox, P. L. High-density lipoprotein stimulates endothelial cell movement by a mechanism distinct from basic fibroblast growth factor. Circ. Res. 74, 1149\u20131156 (1994).","journal-title":"Circ. Res."},{"key":"BFnrneph2015180_CR26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0021-9150(95)05774-9","volume":"123","author":"T Tamagaki","year":"1996","unstructured":"Tamagaki, T. et al. Effects of high-density lipoproteins on intracellular pH and proliferation of human vascular endothelial cells. Atherosclerosis 123, 73\u201382 (1996).","journal-title":"Atherosclerosis"},{"key":"BFnrneph2015180_CR27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/BF02633513","volume":"17","author":"JP Tauber","year":"1981","unstructured":"Tauber, J. P. et al. High density lipoproteins and the growth of vascular endothelial cells in serum-free medium. In Vitro 17, 519\u2013530 (1981).","journal-title":"In Vitro"},{"key":"BFnrneph2015180_CR28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00281-011-0285-5","volume":"34","author":"V van Hinsbergh","year":"2012","unstructured":"van Hinsbergh, V. Endothelium\u2014role in regulation of coagulation and inflammation. Semin. Immunopathol. 34, 93\u2013106 (2012).","journal-title":"Semin. Immunopathol."},{"key":"BFnrneph2015180_CR29","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1161\/01.RES.0000225982.01988.93","volume":"98","author":"C Mineo","year":"2006","unstructured":"Mineo, C. et al. Endothelial and antithrombotic actions of HDL. Circ. Res. 98, 1352\u20131364 (2006).","journal-title":"Circ. Res."},{"key":"BFnrneph2015180_CR30","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1161\/01.ATV.15.8.1131","volume":"15","author":"A Weidtmann","year":"1995","unstructured":"Weidtmann, A. et al. Mildly oxidized LDL induces platelet aggregation through activation of phospholipase A2. Arterioscler. Thromb. Vasc. Biol. 15, 1131\u20131138 (1995).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrneph2015180_CR31","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1440-1681.2010.05377.x","volume":"37","author":"JR Nofer","year":"2010","unstructured":"Nofer, J. R., Brodde, M. F. & Kehrel, B. E. High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Clin. Exp. Pharmacol. Physiol. 37, 726\u201335 (2010).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"BFnrneph2015180_CR32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2362.1977.tb01652.x","volume":"7","author":"E Gherardi","year":"1977","unstructured":"Gherardi, E. et al. Relationship among the concentrations of serum lipoproteins and changes in their chemical composition in patients with untreated nephrotic syndrome. Eur. J. Clin. Invest. 7, 563\u2013570 (1977).","journal-title":"Eur. J. Clin. Invest."},{"key":"BFnrneph2015180_CR33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0021-9150(85)90181-9","volume":"54","author":"E Muls","year":"1985","unstructured":"Muls, E. et al. Lipoprotein distribution and composition in the human nephrotic syndrome. Atherosclerosis 54, 225\u2013237 (1985).","journal-title":"Atherosclerosis"},{"key":"BFnrneph2015180_CR34","first-page":"159","volume-title":"The HDL Handbook","author":"A Lusana","year":"2014","unstructured":"Lusana, A. et al. in The HDL Handbook (ed. Komoda, T.) 159\u2013194 (Academic Press, 2014)."},{"key":"BFnrneph2015180_CR35","first-page":"F823","volume":"49","author":"ND Vaziri","year":"2001","unstructured":"Vaziri, N. D., Liang, K. & Parks, J. S. Acquired lecithin: cholesterol acyltransferase (LCAT) deficiency in nephrotic syndrome. Am. J. Physiol. 49, F823\u2013F829 (2001).","journal-title":"Am. J. Physiol."},{"key":"BFnrneph2015180_CR36","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1021\/bi952242v","volume":"35","author":"Y Zhao","year":"1996","unstructured":"Zhao, Y. & Marcel, Y. L. Serum albumin is a significant intermediate in cholesterol transfer between cells and lipoproteins. Biochemistry 35, 7174\u20137180 (1996).","journal-title":"Biochemistry"},{"key":"BFnrneph2015180_CR37","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0022-2275(20)41339-2","volume":"33","author":"P Moulin","year":"1992","unstructured":"Moulin, P., Appel, G. B., Ginsberg, H. N. & Tall, A. R. Increased concentration of plasma cholesteryl ester transfer protein in nephrotic syndrome: role in dyslipidemia. J. Lipid Res. 33, 1817\u20131822 (1992).","journal-title":"J. Lipid Res."},{"key":"BFnrneph2015180_CR38","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/01.ATV.17.11.2559","volume":"17","author":"S Braschi","year":"1997","unstructured":"Braschi, S. et al. Role of lipoprotein-bound NEFAs in enhancing the specific activity of plasma CETP in the nephrotic syndrome. Arterioscler. Thromb. Vasc. Biol. 17, 2559\u20132567 (1997).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrneph2015180_CR39","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.clinbiochem.2007.04.016","volume":"40","author":"C Zhang","year":"2007","unstructured":"Zhang, C. et al. Effect of hypoalbuminemia on the increased serum cholesteryl ester transfer protein concentration in children with idiopathic nephrotic syndrome. Clin. Biochem. 40, 869\u2013875 (2007).","journal-title":"Clin. Biochem."},{"key":"BFnrneph2015180_CR40","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1523-1755.2004.00373.x","volume":"65","author":"GC Shearer","year":"2004","unstructured":"Shearer, G. C., Couser, W. G. & Kaysen, G. A. Nephrotic livers secrete normal VLDL that acquire structural and functional defects following interaction with HDL. Kidney Int. 65, 228\u2013237 (2004).","journal-title":"Kidney Int."},{"key":"BFnrneph2015180_CR41","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1046\/j.1523-1755.1999.00585.x","volume":"56","author":"K Liang","year":"1999","unstructured":"Liang, K & Vaziri, N. D. Downregulation of hepatic high-density lipoprotein receptor, SR-B1 in nephrotic syndrome. Kidney Int. 56, 621\u2013626 (1999).","journal-title":"Kidney Int."},{"key":"BFnrneph2015180_CR42","doi-asserted-by":"crossref","first-page":"6538","DOI":"10.1073\/pnas.100114397","volume":"97","author":"M Ikemoto","year":"2000","unstructured":"Ikemoto, M. et al. Identification of a PDZ-domain-containing protein that interacts with the scavenger receptor class B type I. Proc. Natl Acad. Sci. USA 97, 6538\u20136543 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneph2015180_CR43","first-page":"524","volume":"103","author":"ND Vaziri","year":"2011","unstructured":"Vaziri, N. D., Gollapudi, P., Han, S., Farahmand, G. & Moradi, H. Upregulation of hepatic HDL endocytic receptor and PDZK-1 dependent downregulation of HDL docking receptor in nephrotic syndrome. Nephrol. Dial. Transplant. 103, 524\u2013533 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2015180_CR44","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nature01250","volume":"421","author":"LO Martinez","year":"2003","unstructured":"Martinez, L. O. et al. Ectopic \u03b2-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 421, 75\u201379 (2003).","journal-title":"Nature"},{"key":"BFnrneph2015180_CR45","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1172\/JCI111548","volume":"74","author":"DW Garber","year":"1984","unstructured":"Garber, D. W. et al. Catabolism of very low density lipoproteins in experimental nephrosis. J. Clin. Invest. 74, 1375\u20131383 (1984).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph2015180_CR46","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/ki.1997.263","volume":"51","author":"K Liang","year":"1997","unstructured":"Liang, K. & Vaziri N. D. Down-regulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int. 51, 1933\u20131937 (1997).","journal-title":"Kidney Int."},{"key":"BFnrneph2015180_CR47","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1046\/j.1523-1755.2003.00281.x","volume":"64","author":"T Sato","year":"2003","unstructured":"Sato, T., Liang, K. & Vaziri, N. D. Protein restriction and AST-120 improve lipoprotein lipase, hepatic lipase and VLDL receptor in focal glomerulosclerosis. Kidney Int. 64, 1780\u20131786 (2003).","journal-title":"Kidney Int."},{"key":"BFnrneph2015180_CR48","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10157-013-0847-z","volume":"18","author":"ND Vaziri","year":"2014","unstructured":"Vaziri, N. D. Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease. Clin. Exp. Nephrol. 18, 265\u2013268 (2014).","journal-title":"Clin. Exp. Nephrol."},{"key":"BFnrneph2015180_CR49","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1523-1755.2001.00478.x","volume":"59","author":"GC Shearer","year":"2001","unstructured":"Shearer, G. C. et al. Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome. Kidney Int. 59, 179\u2013189 (2001).","journal-title":"Kidney Int."},{"key":"BFnrneph2015180_CR50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0026-0495(90)90155-6","volume":"39","author":"S Furukawa","year":"1990","unstructured":"Furukawa, S., Hirano, T., Mamo, J. C., Nagano, S. & Takahashi, T. Catabolic defect of triglyceride is associated with abnormal very-low-density lipoprotein in experimental nephrosis. Metabolism 39, 101\u2013107 (1990).","journal-title":"Metabolism"},{"key":"BFnrneph2015180_CR51","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1523-1755.2002.00104.x","volume":"61","author":"T Sato","year":"2002","unstructured":"Sato, T., Liang, K. & Vaziri, N. D. Downregulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis. Kidney Int. 61, 157\u2013162 (2002).","journal-title":"Kidney Int."},{"key":"BFnrneph2015180_CR52","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0022-2143(97)90038-X","volume":"130","author":"K Liang","year":"1997","unstructured":"Liang, K. & Vaziri, N. D. Gene expression of lipoprotein lipase in experimental nephrosis. J. Lab. Clin. Med. 130, 387\u2013394 (1997).","journal-title":"J. Lab. Clin. Med."},{"key":"BFnrneph2015180_CR53","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrneph.2010.36","volume":"6","author":"ND Vaziri","year":"2010","unstructured":"Vaziri, N. D., Navab, M. & Fogelman, A. M. HDL metabolism and activity in chronic kidney disease. Nat. Rev. Nephrol. 6, 287\u2013296 (2010).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph2015180_CR54","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0272-6386(12)80030-8","volume":"21","author":"PO Attman","year":"1993","unstructured":"Attman, P. O., Samuelsson, O. & Alaupovic, P. Lipoprotein metabolism and renal failure. Am. J. Kidney Dis. 21, 573\u2013592 (1993).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2015180_CR55","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2010111144","volume":"22","author":"M Holzer","year":"2011","unstructured":"Holzer, M. et al. Uremia alters HDL composition and function. J. Am. Soc. Nephrol. 22, 1631\u201341 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2015180_CR56","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.jrn.2013.01.022","volume":"23","author":"H Moradi","year":"2013","unstructured":"Moradi, H., Vaziri, N. D., Kashyap, M. L., Said, H. M. & Kalantar-Zadeh, K. Role of HDL dysfunction in end-stage renal disease: a double-edged sword. J. Ren. Nutr. 23, 203\u2013206 (2013).","journal-title":"J. Ren. Nutr."},{"key":"BFnrneph2015180_CR57","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.atherosclerosis.2011.10.038","volume":"220","author":"H Honda","year":"2012","unstructured":"Honda, H. et al. Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients. Atherosclerosis 220, 493\u2013501 (2012).","journal-title":"Atherosclerosis"},{"key":"BFnrneph2015180_CR58","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrneph.2014.169","volume":"10","author":"ND Vaziri","year":"2014","unstructured":"Vaziri, N. D. Risk factors: HDL-cholesterol levels and mortality in patients with ESRD. Nat. Rev. Nephrol. 10, 621\u2013623 (2014).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph2015180_CR59","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/ndt\/gfu022","volume":"29","author":"H Moradi","year":"2014","unstructured":"Moradi, H. et al. Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. Nephrol. Dial. Transplant. 29, 1554\u20131562 (2014).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2015180_CR60","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1097\/01.ASN.0000117286.85443.7D","volume":"15","author":"K Okubo","year":"2004","unstructured":"Okubo, K. et al. Abnormal HDL apolipoprotein A-I and A-II kinetics in hemodialysis patients: a stable isotope study. J. Am. Soc. Nephrol. 15, 1008\u20131015 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2015180_CR61","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/ndt\/14.6.1462","volume":"14","author":"ND Vaziri","year":"1999","unstructured":"Vaziri, N. D., Deng, G. & Liang, K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol. Dial. Transplant. 14, 1462\u20131466 (1999).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2015180_CR62","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1681\/ASN.V52193","volume":"5","author":"VS Kamanna","year":"1994","unstructured":"Kamanna, V. S. et al. Uremic serum subfraction inhibits apolipoprotein A-I production by a human hepatoma cell line. J. Am. Soc. Nephrol. 5, 193\u2013200 (1994).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2015180_CR63","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.trsl.2012.11.001","volume":"161","author":"H Moradi","year":"2013","unstructured":"Moradi, H., Said, H. M. & Vaziri, N. D. Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production. Transl. Res. 161, 477\u2013485 (2013).","journal-title":"Transl. Res."},{"key":"BFnrneph2015180_CR64","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1744-9987.2012.01102.x","volume":"16","author":"M Pruijm","year":"2012","unstructured":"Pruijm, M. et al. High prevalence of anti-apolipoprotein\/A-1 autoantibodies in maintenance hemodialysis and association with dialysis vintage. Ther. Apher. Dial. 16, 588\u2013594 (2012).","journal-title":"Ther. Apher. Dial."},{"key":"BFnrneph2015180_CR65","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/01.ASN.0000046962.43220.8A","volume":"14","author":"T Miida","year":"2003","unstructured":"Miida, T. et al. LCAT-dependent conversion of pre\u03b21-HDL into \u03b1-migrating HDL is severely delayed in hemodialysis patients. J. Am. Soc. Nephrol. 14, 732\u2013738 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2015180_CR66","first-page":"S26","volume":"1978","author":"GF Guarnieri","year":"1978","unstructured":"Guarnieri, G. F. et al. Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int. Suppl. 1978, S26\u2013S30 (1978).","journal-title":"Kidney Int. Suppl."},{"key":"BFnrneph2015180_CR67","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/ki.1992.238","volume":"41","author":"T Shoji","year":"1992","unstructured":"Shoji, T., Nishizawa, Y., Nishitani, H., Billheimer, J. T. & Sturley, S. L. Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int. 41, 1653\u20131661 (1992).","journal-title":"Kidney Int."},{"key":"BFnrneph2015180_CR68","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1046\/j.1523-1755.2003.00911.x","volume":"63","author":"ND Vaziri","year":"2003","unstructured":"Vaziri, N. D, Sato, T. & Liang, K. Molecular mechanism of altered cholesterol metabolism in focal glomerulosclerosis. Kidney Int. 63, 1756\u20131763 (2003).","journal-title":"Kidney Int."},{"key":"BFnrneph2015180_CR69","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1046\/j.1523-1755.2001.00734.x","volume":"59","author":"ND Vaziri","year":"2001","unstructured":"Vaziri, N. D, Liang, K. & Parks, J. S. Downregulation of lecithin: cholesterol acyltransferase (LCAT) in chronic renal failure. Kidney Int. 59, 2192\u20132196 (2001).","journal-title":"Kidney Int."},{"key":"BFnrneph2015180_CR70","doi-asserted-by":"crossref","first-page":"F539","DOI":"10.1152\/ajprenal.00074.2004","volume":"288","author":"K Liang","year":"2005","unstructured":"Liang, K., Kim, C. & Vaziri, N. D. HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure. Am. J. Physiol. Renal Physiol. 288, F539\u2013F544 (2005).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph2015180_CR71","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1046\/j.1523-1755.2001.00734.x","volume":"59","author":"ND Vaziri","year":"2001","unstructured":"Vaziri, N. D., Liang, K. & Parks, J. S. Downregulation of hepatic lecithin: cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int. 59, 2192\u20132196 (2001).","journal-title":"Kidney Int."},{"key":"BFnrneph2015180_CR72","doi-asserted-by":"crossref","first-page":"E676","DOI":"10.1152\/ajpendo.00364.2001","volume":"283","author":"K Liang","year":"2002","unstructured":"Liang, K. & Vaziri, N. D. Upregulation of Acyl-CoA: cholesterol acyltransferase (ACAT) in chronic renal failure. Am. J. Physiol. Endocrinol. Metab. 283, E676\u2013E681 (2002).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"BFnrneph2015180_CR73","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000210020","volume":"30","author":"H Moradi","year":"2009","unstructured":"Moradi, H., Yuan, J., Ni, Z., Norris, K. & Vaziri, N. D. Reverse cholesterol transport pathway in experimental chronic kidney disease. Am. J. Nephrol. 30, 147\u2013154 (2009).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph2015180_CR74","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1089\/ars.2010.3640","volume":"14","author":"M Holzer","year":"2011","unstructured":"Holzer, M. et al. Protein carbamylation renders high-density lipoprotein dysfunctional. Antioxid. Redox Signal. 14, 2337\u20132346 (2011).","journal-title":"Antioxid. Redox Signal."},{"key":"BFnrneph2015180_CR75","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1089\/ars.2011.4403","volume":"17","author":"M Holzer","year":"2012","unstructured":"Holzer, M. et al. Myeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: novel pathways generating dysfunctional high-density lipoprotein. Antioxid. Redox Signal. 17, 1043\u20131052 (2012).","journal-title":"Antioxid. Redox Signal."},{"key":"BFnrneph2015180_CR76","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1161\/ATVBAHA.113.303044","volume":"34","author":"B Hewing","year":"2014","unstructured":"Hewing, B. et al. Effects of native and myeloperoxidase-modified apolipoprotein A-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 34, 779\u2013789 (2014).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrneph2015180_CR77","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/01.hco.0000231402.87232.aa","volume":"21","author":"B Shao","year":"2006","unstructured":"Shao, B, Oda, M. N., Oram, J. F. & Heinecke, J. W. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr. Opin. Cardiol. 21, 322\u2013328 (2006).","journal-title":"Curr. Opin. Cardiol."},{"key":"BFnrneph2015180_CR78","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trsl.2008.11.007","volume":"153","author":"H Moradi","year":"2009","unstructured":"Moradi, H., Pahl, M. V., Elahimehr, R. & Vaziri, N. D. Impaired antioxidant activity of HDL in chronic kidney disease. Transl. Res. 153, 77\u201385 (2009).","journal-title":"Transl. Res."},{"key":"BFnrneph2015180_CR79","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/sj.ki.5002491","volume":"72","author":"K Kalantar-Zadeh","year":"2007","unstructured":"Kalantar-Zadeh, K., Kopple, J. D., Kamranpour, N., Fogelman, A. M & Navab, M. HDL inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int. 72, 1149\u20131156 (2007).","journal-title":"Kidney Int."},{"key":"BFnrneph2015180_CR80","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/ki.1997.263","volume":"51","author":"K Liang","year":"1997","unstructured":"Liang, K. & Vaziri, N. D. Down-regulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int. 51, 1933\u20131937 (1997).","journal-title":"Kidney Int."},{"key":"BFnrneph2015180_CR81","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1046\/j.1523-1755.2003.00281.x","volume":"64","author":"T Sato","year":"2003","unstructured":"Sato, T., Liang, K. & Vaziri, N. D. Protein restriction and AST-120 improve lipoprotein lipase, hepatic lipase and VLDL receptor in focal glomerulosclerosis. Kidney Int. 64, 1780\u20131786 (2003).","journal-title":"Kidney Int."},{"key":"BFnrneph2015180_CR82","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1172\/JCI118657","volume":"97","author":"M Klin","year":"1996","unstructured":"Klin, M., Smogorzewski, M., Ni, Z., Zhang, G. & Massry, S. G. Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. J. Clin. Invest. 97, 2167\u20132173 (1996).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph2015180_CR83","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.jacc.2012.09.013","volume":"60","author":"S Yamamoto","year":"2012","unstructured":"Yamamoto, S. et al. dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J. Am. Coll. Cardiol. 60, 2372\u20132379 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrneph2015180_CR84","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1388-1981(00)00157-8","volume":"1529","author":"JF Oram","year":"2000","unstructured":"Oram, J. F. Tangier disease and ABCA1. Biochim. Biophys. Acta 1529, 321\u2013330 (2000).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnrneph2015180_CR85","doi-asserted-by":"crossref","first-page":"F1297","DOI":"10.1152\/ajprenal.90761.2008","volume":"296","author":"HJ Kim","year":"2009","unstructured":"Kim, H. J., Moradi, H. & Vaziri, N. D. Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am. J. Physiol. Renal Physiol. 296, F1297\u2013F1306 (2009).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph2015180_CR86","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/ajkd.2001.25196","volume":"38","author":"H Kimura","year":"2001","unstructured":"Kimura, H., Miyazaki, R., Suzuki, S., Gejyo, F. & Yoshida, H. Cholesteryl ester transfer protein as a protective factor against vascular disease in hemodialysis patients. Am. J. Kidney Dis. 38, 70\u201376 (2001).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2015180_CR87","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/ndt\/gfp120","volume":"24","author":"MV Pahl","year":"2009","unstructured":"Pahl, M. V., Ni, Z., Sepassi, L. & Vaziri, N. D. Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin: cholesterol aacyltransferase in end-stage renal disease. Nephrol. Dial. Transplant. 24, 2541\u20132546 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2015180_CR88","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/ndt\/14.6.1462","volume":"14","author":"ND Vaziri","year":"1999","unstructured":"Vaziri, N. D., Deng, G. & Liang, K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol. Dial. Transplant. 14, 1462\u20131466 (1999).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2015180_CR89","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1681\/ASN.V9112082","volume":"9","author":"TF Dantoine","year":"1998","unstructured":"Dantoine, T. F. et al. Decrease of serum paraoxonase activity in chronic renal failure. J. Am. Soc. Nephrol. 9, 2082\u20132088 (1998).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2015180_CR90","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1161\/01.CIR.0000103624.14436.4B","volume":"108","author":"BJ Ansell","year":"2003","unstructured":"Ansell, B. J. et al. Inflammatory\/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-denisty lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108, 2751\u20132756 (2003).","journal-title":"Circulation"},{"key":"BFnrneph2015180_CR91","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/MOL.0b013e3282364a17","volume":"18","author":"BJ Ansell","year":"2007","unstructured":"Ansell, B. J., Fonarow, G. C. & Fogelman, A. M. The paradox of dysfunctional high-density lipoprotein. Curr. Opin. Lipidol. 18, 427\u2013434 (2007).","journal-title":"Curr. Opin. Lipidol."},{"key":"BFnrneph2015180_CR92","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2215\/CJN.03600807","volume":"3","author":"CC Szeto","year":"2008","unstructured":"Szeto, C. C et al. Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin. J. Am. Soc. Nephrol. 3, 431\u2013436 (2008).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2015180_CR93","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.2174\/0929867321666140414103455","volume":"21","author":"M Rizzo","year":"2014","unstructured":"Rizzo, M. et al. Subfractions and subpopulations of HDL: an update. Curr. Med. Chem. 21, 2881\u20132891 (2014).","journal-title":"Curr. Med. Chem."},{"key":"BFnrneph2015180_CR94","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.plipres.2012.03.003","volume":"51","author":"A Otocka-Kmiecik","year":"2012","unstructured":"Otocka-Kmiecik, A. et al. HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog. Lipid Res. 51, 314\u2013324 (2012).","journal-title":"Prog. Lipid Res."},{"key":"BFnrneph2015180_CR95","first-page":"F642","volume":"274","author":"ND Vaziri","year":"1998","unstructured":"Vaziri, N. D., Ni, Z., Wang, X. Q., Oveisi, F. & Zhou, X. J. Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH. Am. J. Physiol. 274, F642\u2013F649 (1998).","journal-title":"Am. J. Physiol."},{"key":"BFnrneph2015180_CR96","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/hy0102.100540","volume":"39","author":"ND Vaziri","year":"2002","unstructured":"Vaziri, N. D., Ni, Z., Oveisi, F. & Liang, K. Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 39, 135\u2013141 (2002).","journal-title":"Hypertension"},{"key":"BFnrneph2015180_CR97","doi-asserted-by":"crossref","first-page":"12936","DOI":"10.1038\/srep12936","volume":"7","author":"YY Zhao","year":"2015","unstructured":"Zhao, Y. Y. et al. Metabolic analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis, and Nrf2 dysfunction in aristolochic acid-induced nephropathy. Sci. Rep. 7, 12936 (2015).","journal-title":"Sci. Rep."},{"key":"BFnrneph2015180_CR98","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/bs.acc.2014.11.002","volume":"68","author":"YY Zhao","year":"2015","unstructured":"Zhao, Y. Y., Vaziri, N. D & Lin, R. C. Lipidomics: new insight into kidney disease. Adv. Clin. Chem. 68, 153\u2013175 (2015).","journal-title":"Adv. Clin. Chem."},{"key":"BFnrneph2015180_CR99","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2215\/CJN.03600807","volume":"3","author":"CC Szeto","year":"2008","unstructured":"Szeto, C. C. et al. Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin. J. Am. Soc. Nephrol. 3, 431\u2013436 (2008).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2015180_CR100","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1093\/ndt\/gfl273","volume":"21","author":"S Gon\u00e7alves","year":"2006","unstructured":"Gon\u00e7alves, S. et al. Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. Nephrol. Dial. Transplant. 21, 2788\u20132794 (2006).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2015180_CR101","doi-asserted-by":"publisher","unstructured":"Vaziri, N. D., Zhao, Y. Y. & Pahl, M. V. Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrol. Dial. Transplant. http:\/\/dx.doi.org\/10.1093\/ndt\/gfv095 (2015).","DOI":"10.1093\/ndt\/gfv095"},{"key":"BFnrneph2015180_CR102","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/ajkd.2001.25174","volume":"38","author":"ND Vaziri","year":"2001","unstructured":"Vaziri, N. D. Effect of chronic renal failure on nitric oxide metabolism. Am. J. Kidney Dis. 38, 574\u2013579 (2001).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2015180_CR103","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1681\/ASN.2005101119","volume":"17","author":"SM Bode-Boger","year":"2006","unstructured":"Bode-Boger, S. M. et al. Symmetrical di-methylarginine: a new combined parameter for renal function and extent of coronary artery disease. J. Am. Soc. Nephrol. 17, 1128\u20131134 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2015180_CR104","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1093\/ndt\/gfl292","volume":"21","author":"JT Kielstein","year":"2006","unstructured":"Kielstein, J. T. et al. Symmetric di-methylarginine (SDMA) as endogenous marker of renal function\u2014a meta-analysis. Nephrol. Dial. Transplant. 21, 2446\u20132451 (2006).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2015180_CR105","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/ki.1996.515","volume":"50","author":"ND Vaziri","year":"1996","unstructured":"Vaziri, N. D. & Liang, K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int. 50, 1928\u20131935 (1996).","journal-title":"Kidney Int."},{"key":"BFnrneph2015180_CR106","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrneph.2012.33","volume":"8","author":"M Epstein","year":"2012","unstructured":"Epstein, M. & Vaziri, N. D. Role of statins in the management of dyslipidemia of chronic kidney disease: current concepts and emerging treatment paradigms. Nat. Rev. Nephrol. 8, 214\u2013223 (2012).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph2015180_CR107","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238\u2013248 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2015180_CR108","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstrom","year":"2009","unstructured":"Fellstrom, B. C. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395\u20131407 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2015180_CR109","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.2215\/CJN.09121010","volume":"6","author":"W M\u00e4rz","year":"2011","unstructured":"M\u00e4rz, W. et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin. J. Am. Soc. Nephrol. 6, 1316\u20131325 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2015180_CR110","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","volume":"8","author":"BA Golomb","year":"2008","unstructured":"Golomb, B. A. & Evans, M. A. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am. J. Cardiovasc. Drugs 8, 373\u2013418 (2008).","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"BFnrneph2015180_CR111","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.phrs.2015.07.008","volume":"99","author":"M Banach","year":"2015","unstructured":"Banach, M. et al. Statin therapy and plasma coenzyme Q10 concentrations\u2014a systematic review and meta-analysis of placebo-controlled trials. Pharmacol. Res. 99, 329\u2013336 (2015).","journal-title":"Pharmacol. Res."},{"key":"BFnrneph2015180_CR112","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0272-6386(04)01082-0","volume":"44","author":"M Tonelli","year":"2004","unstructured":"Tonelli, M., Collins, D., Robins, S., Bloomfield, H. & Curhan, G. C. effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. Am. J. Kidney Dis. 44, 832\u2013839 (2004).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2015180_CR113","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1523-1755.2004.00862.x","volume":"66","author":"M Tonelli","year":"2004","unstructured":"Tonelli, M., Collins, D., Robins, S., Bloomfield, H. & Curhan, G. C. for the Veterans' Affairs High-Density Lipoprotein intervention Trial (VA-HiT) investigators. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int. 66, 1123\u20131130 (2004).","journal-title":"Kidney Int."},{"key":"BFnrneph2015180_CR114","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2796.2005.01528.x","volume":"258","author":"LA Carlson","year":"2005","unstructured":"Carlson, L. A. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med. 258, 94\u2013114 (2005).","journal-title":"J. Intern. Med."},{"key":"BFnrneph2015180_CR115","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/1523-1747.ep12499963","volume":"98","author":"JD Morrow","year":"1992","unstructured":"Morrow, J. D., Awad, J. A., Oates, J. A. & Roberts, L. J. 2nd. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J. Invest. Dermatol. 98, 812\u2013815 (1992).","journal-title":"J. Invest. Dermatol."},{"key":"BFnrneph2015180_CR116","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jacl.2011.12.008","volume":"6","author":"V Rajanna","year":"2012","unstructured":"Rajanna, V., Campbell, K. B., Leimberger, J., Mohanty, B. D & Guyton, J. R. Elevation of fasting morning glucose relative to hemoglobin A1c in normoglycemic patients treated with niacin and with statins J. Clin. Lipidol. 6, 168\u2013173 (2012).","journal-title":"J. Clin. Lipidol."},{"key":"BFnrneph2015180_CR117","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cld.2007.06.010","volume":"11","author":"SS Bhardwaj","year":"2007","unstructured":"Bhardwaj, S. S. & Chalasani, N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin. Liver Dis. 11, 597\u2013613 (2007).","journal-title":"Clin. Liver Dis."},{"key":"BFnrneph2015180_CR118","doi-asserted-by":"publisher","unstructured":"Goldie, C. et al. Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. Heart http:\/\/dx.doi.org\/10.1136\/heartjnl-2015-308055 (2015).","DOI":"10.1136\/heartjnl-2015-308055"}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2015.180.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2015.180","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2015.180.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:46:24Z","timestamp":1684457184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2015.180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,16]]},"references-count":118,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["BFnrneph2015180"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2015.180","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,16]]},"assertion":[{"value":"16 November 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}